Protalix Biotherapeutics Ownership
| PLX Stock | USD 2.49 0.13 5.51% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 81 M | Current Value 81 M | Avarage Shares Outstanding 24.2 M | Quarterly Volatility 23.7 M |
Protalix |
Protalix Stock Ownership Analysis
About 14.0% of the company outstanding shares are owned by corporate insiders. The book value of Protalix Biotherapeutics was at this time reported as 0.57. The company last dividend was issued on the 20th of December 2019. Protalix Biotherapeutics had 1:10 split on the 20th of December 2019. Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company was founded in 1993 and is based in Hackensack, New Jersey. Protalix Biotherapeutics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 202 people. To find out more about Protalix Biotherapeutics contact Dror Bashan at 972 4 902 8100 or learn more at https://www.protalix.com.Besides selling stocks to institutional investors, Protalix Biotherapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Protalix Biotherapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Protalix Biotherapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Protalix Biotherapeutics Quarterly Liabilities And Stockholders Equity |
|
Protalix Biotherapeutics Insider Trades History
About 14.0% of Protalix Biotherapeutics are currently held by insiders. Unlike Protalix Biotherapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Protalix Biotherapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Protalix Biotherapeutics' insider trades
Protalix Biotherapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Protalix Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Protalix Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Protalix Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Protalix Biotherapeutics Outstanding Bonds
Protalix Biotherapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Protalix Biotherapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Protalix bonds can be classified according to their maturity, which is the date when Protalix Biotherapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| PL 1618 15 APR 26 Corp BondUS74368CBC73 | View | |
| US74368CAX20 Corp BondUS74368CAX20 | View | |
| US743674BE29 Corp BondUS743674BE29 | View | |
| US74368CAY03 Corp BondUS74368CAY03 | View | |
| PRXNA 3832 08 FEB 51 Corp BondUS74365PAE88 | View | |
| PL 5366 06 JAN 26 Corp BondUS74368CBQ69 | View | |
| PRXNA 4027 03 AUG 50 Corp BondUS74365PAD06 | View | |
| PRXNA 3257 19 JAN 27 Corp BondUS74365PAG37 | View |
Protalix Biotherapeutics Corporate Filings
8K | 17th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 5th of November 2024 Other Reports | ViewVerify | |
F4 | 24th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 1st of July 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.